Discussion on Venetoclax Data and Personalizing Therapy for Translocation 1114 Myeloma

Discussion of clinical abstracts presented at the conference focusing on the data of a combination treatment of Venetoclax, Deratumumab, and dexamethasone for translocation 1114 disease, with a high overall response rate and complete response rate. Emphasis on personalizing therapy, excitement about long-term follow-up data, and frustration about the delay in biomarker-driven treatments.

Transcript

Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.